Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Relivyx Plus is a prescription topical pain-relief combination kit that contains **lidocaine 5% patches** and a **menthol roll-on gel**. The product is a **small-molecule combination** intended for local analgesia, with lidocaine acting primarily as a blocker of voltage-gated sodium channels in peripheral nerves to reduce initiation and conduction of pain signals, while menthol provides topical counterirritant and cooling analgesic effects that are generally mediated through sensory nerve modulation. Available information indicates the lidocaine patch component contains 700 mg lidocaine in an adhesive matrix on a polyester felt backing. Public labeling indicates the product is marked **Rx Only**, but also states that it has **not been found by FDA to be safe and effective** and that the labeling has **not been approved by FDA**, consistent with an unapproved drug product. A specific sponsoring developer or manufacturer is not clearly identifiable from the provided information.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Relivyx Plus.